FINNENCE ▪ THE WIRE FILE
THE WIRE · № 61043
Price move▼ Bearish
iShares Biotech ETF -2.2%
KINDPrice move
DIRECTION▼ Bearish
SOURCES1
ENTITIES3
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 01:49 UTC
LAST UPDATE2026-10-02 01:49 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Biotech weakness signals risk-off in long-duration healthcare names sensitive to rates and trial news.
Biotech softens as rate-sensitive growth cools
CATALYST TO WATCH
Trial data and rate expectations
MAIN RISK
M&A news could quickly reverse sentiment
FULL DISPATCH
iShares Biotech ETF (IBB) moved -2.2% in the latest period (1d). Close: 205.96, prior: 210.53.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
←CORRELATIONshares Healthcare
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Eli Lilly and Company2026-10-01 12:00 UTC
Phase 3 results posted: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Eli Lilly and Company2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — Biosplice Therapeutics, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — Biosplice Therapeutics, Inc.2026-10-01 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) — BioXcel Therapeutics Inc2026-10-01 12:00 UTC
Phase 3 results posted: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) — BioXcel Therapeutics Inc2026-10-01 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.